Abstract:
The present invention relates to crystalline forms of L-malic acid salt of sunitinib and its preparation. The crystalline forms of the present invention are designated as Form V and Form VI of L-malic acid salt of sunitinib. Formula (I).
Abstract:
The present invention relates to processes for the preparation of Form I and Form II of palonosetron hydrochloride. The present invention further relates to a method of determining the polymorphic forms of palonosetron hydrochloride using Fourier-Transform Infra-red (FTIR) method.
Abstract:
The present invention provides processes for the preparation of vardenafil, its pharmaceutically acceptable salts, hydrates and intermediates.
Abstract:
The present invention relates to a polymorphic form of olmesartan medoxomil and a process for the preparation of crystalline olmesartan medoxomil.
Abstract:
The present invention relates to a process for preparing a carbapenem antibiotic composition. The present invention further relates to a carbapenem antibiotic composition substantially free of degradation impurities. The present invention further relates to a polymorphic form of ertapenem mono sodium designated as Form D and its preparation.
Abstract:
The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.
Abstract:
The present invention provides a process for preparing orlistat from amino orlistat using Pivaloyl Formic Anhydride (PFA) as an alkanoylating agent.
Abstract:
The present invention relates to polymorphic forms of milnacipran hydrochloride. The polymorphic forms are designated as Form (I), Form (II), Form (III), Form (IV) and Form V of milnacipran hydrochloride. The present invention also relates to processes for the preparation of the polymorphic forms.
Abstract:
The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.